Status:
TERMINATED
Asthma/Steroid Withdrawal Study
Lead Sponsor:
University of Alberta
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The investigators propose to study the patterns of metabolite changes in subjects with asthma to determine if there is a predictable pattern prior to, and post, clinical exacerbation. Hypothesis: 1. ...
Detailed Description
Methods: We propose to study 20, non-smoking, asthmatic adults. Subjects will be recruited from outpatient asthma clinics in Edmonton. All subjects will meet GINA criteria for mild persistent to mode...
Eligibility Criteria
Inclusion
- Non-smoker (less than 1 pack-year).
- Age greater than 18 years old.
- Ability to obtain informed consent.
- Pulmonary Function Tests demonstrating greater than 12% FEV1 reversibility following beta agonist OR a methacholine challenge consistent with airways hyper-reactivity.
- Evidence of atopy on standardized skin test battery.
- Mild to moderate persistent asthma classification by GINA guidelines.
- No severe exacerbations in the preceding 3 months (defined as emergency room visit, course of oral prednisone or hospitalization).
- Access to internet.
Exclusion
- Unstable asthma.
- Patient not on inhaled corticosteroids.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00395239
Start Date
October 1 2006
End Date
October 1 2015
Last Update
May 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7